Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It is prescribed for the management of major depressive disorder in adult patients, helping to improve mood, sleep and appetite, and is often selected for its sedative properties that may benefit individuals with insomnia associated with depression.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and on‑time delivery to diverse markets.

Mirtazapine is indicated for conditions within the depressive disorder spectrum.

- Major depressive disorder: alleviates depressive symptoms, improves mood, sleep and appetite in adult patients.

Mirtazapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: sedation or sleepiness, especially early in therapy. - Increased appetite/weight gain: heightened hunger leading to weight increase. - Dry mouth: reduced salivation causing oral dryness.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: rare occurrence of convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis.

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure safe use. - Assess psychiatric history: evaluate for bipolar disorder or suicidal ideation before initiating therapy. - Monitor weight and metabolic parameters: track body weight, appetite changes and lipid profile regularly. - Caution in hepatic impairment: adjust use in patients with liver dysfunction. - Avoid abrupt discontinuation: taper dose to reduce risk of withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Mirtazapine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis; a washout period is required. - CNS depressants: combined use can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Anticoagulants (e.g., warfarin): possible alteration of INR, requiring monitoring. - Alcohol: additive central nervous system depression, advise limited consumption.